Background: A clinical decision support tool may improve recognition of hidradenitis suppurativa (HS) and reduce diagnosis delay. Objective: To develop and initially validate a clinical decision support to predict diagnosis of HS and distinguish it from cutaneous abscess of the axilla, groin, perineum, and buttock. Methods: This was a retrospective, cross-sectional analysis between January 2012 and June 2017 (development set) and July 2017 and March 2019 (validation set). We used an electronic records sample of 56 million patients from the Explorys database to identify patients with an ambulatory visit associated with either HS or cutaneous of the axilla, groin, perineum, and buttock. The outcome was predicted probability of HS diagnosis. Results: Development set included 7,974 patients with mean age of 41.4 years, who were predominantly female (66%) and white (62%). Validation set included 1,560 patients with similar demographic composition. Factors which were stronger independent predictors of HS included female sex (OR 2.17 [95% CI 1.96–2.40]); African American race (1.28 [95% CI 1.15–1.44]); increasing BMI (OR 1.05 [95% CI 1.05–1.06)]; history of acne (OR 3.46 [95% CI 2.83–4.23]); Down syndrome (OR 5.35 [95% CI 2.03–14.12]); and prescription for at least 7 opioid medications in the past year (OR 1.05 [95% CI 0.83–1.33]). Up to age 45 years, increasing age was a stronger predictor of HS diagnosis. The simplified model showed good discrimination (c-statistic 0.746 [SE 0.013]) and moderate calibration (calibration intercept –0.260 [SE 0.055]; calibration slope 1.142 [SE 0.076]). Conclusion: This clinical decision support tool shows good performance in predicting diagnosis of HS and distinguishing it from cutaneous abscess that involves the axilla, groin, perineum, and buttock.

1.
Hoffman
LK
,
Ghias
MH
,
Garg
A
,
Hamzavi
IH
,
Alavi
A
,
Lowes
MA
.
Major gaps in understanding and treatment of hidradenitis suppurativa
.
Semin Cutan Med Surg
.
2017
Jun
;
36
(
2
):
86
92
.
[PubMed]
1085-5629
2.
Garg
A
,
Neuren
E
,
Cha
D
,
Kirby
JS
,
Ingram
JR
,
Jemec
GB
, et al
Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global VOICE project
.
J Am Acad Dermatol
.
2020
;
82
(
2
):
366
76
.
[PubMed]
0190-9622
3.
Saunte
DM
,
Boer
J
,
Stratigos
A
,
Szepietowski
JC
,
Hamzavi
I
,
Kim
KH
, et al
Diagnostic delay in hidradenitis suppurativa is a global problem
.
Br J Dermatol
.
2015
Dec
;
173
(
6
):
1546
9
.
[PubMed]
0007-0963
4.
IBM
.
The data curation process.
Watson health informatics overview of mapping, standardization, and indexing. Available at: https://www01.ibm.com/common/ssi/cgibin/ssialias?htmlfid=HPW03025USEN. Accessed June 20, 2020.
5.
U.S. National Library of Medicine Unified Medical Language System (UMLS)
. Systematized Nomenclature of Medicine—Clinicals Terms (SNOMED CT). Available from URL: http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html. Accessed June 20, 2020.
6.
Nelson
SJ
,
Zeng
K
,
Kilbourne
J
,
Powell
T
,
Moore
R
.
Normalized names for clinical drugs: RxNorm at 6 years
.
J Am Med Inform Assoc
.
2011
Jul-Aug
;
18
(
4
):
441
8
.
[PubMed]
1067-5027
7.
McDonald
CJ
,
Huff
SM
,
Suico
JG
,
Hill
G
,
Leavelle
D
,
Aller
R
, et al
LOINC, a universal standard for identifying laboratory observations: a 5-year update
.
Clin Chem
.
2003
Apr
;
49
(
4
):
624
33
.
[PubMed]
0009-9147
8.
Strunk
A
,
Midura
M
,
Papagermanos
V
,
Alloo
A
,
Garg
A
.
Validation of a case-finding algorithm for hidradenitissuppurativa using administrative coding from a clinical database
.
Dermatology
.
2017
;
233
(
1
):
53
7
.
[PubMed]
1018-8665
9.
Wood
AM
,
White
IR
,
Royston
P
.
How should variable selection be performed with multiply imputed data?
Stat Med
.
2008
Jul
;
27
(
17
):
3227
46
.
[PubMed]
0277-6715
10.
Ambler
G
,
Brady
AR
,
Royston
P
.
Simplifying a prognostic model: a simulation study based on clinical data
.
Stat Med
.
2002
Dec
;
21
(
24
):
3803
22
.
[PubMed]
0277-6715
11.
Garg
A
,
Kirby
JS
,
Lavian
J
,
Lin
G
,
Strunk
A
.
Sex- and Age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States
.
JAMA Dermatol
.
2017
Aug
;
153
(
8
):
760
4
.
[PubMed]
2168-6068
12.
Garg
A
,
Lavian
J
,
Lin
G
,
Strunk
A
,
Alloo
A
.
Incidence of hidradenitis suppurativa in the United States: A sex- and age-adjusted population analysis
.
J Am Acad Dermatol
.
2017
Jul
;
77
(
1
):
118
22
.
[PubMed]
0190-9622
13.
Canoui-Poitrine
F
,
Revuz
JE
,
Wolkenstein
P
,
Viallette
C
,
Gabison
G
,
Pouget
F
, et al
Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity
.
J Am Acad Dermatol
.
2009
Jul
;
61
(
1
):
51
7
.
[PubMed]
0190-9622
14.
Garg
A
,
Besen
J
,
Legler
A
,
Lam
CS
.
Factors Associated With Point-of-Care Treatment Decisions for Hidradenitis Suppurativa
.
JAMA Dermatol
.
2016
May
;
152
(
5
):
553
7
.
[PubMed]
2168-6068
15.
Miller
IM
,
Ellervik
C
,
Vinding
GR
,
Zarchi
K
,
Ibler
KS
,
Knudsen
KM
, et al
Association of metabolic syndrome and hidradenitis suppurativa
.
JAMA Dermatol
.
2014
Dec
;
150
(
12
):
1273
80
.
[PubMed]
2168-6068
16.
Revuz
JE
,
Canoui-Poitrine
F
,
Wolkenstein
P
,
Viallette
C
,
Gabison
G
,
Pouget
F
, et al
Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies
.
J Am Acad Dermatol
.
2008
Oct
;
59
(
4
):
596
601
.
[PubMed]
0190-9622
17.
Sartorius
K
,
Emtestam
L
,
Jemec
GB
,
Lapins
J
.
Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
.
Br J Dermatol
.
2009
Oct
;
161
(
4
):
831
9
.
[PubMed]
0007-0963
18.
Schrader
AM
,
Deckers
IE
,
van der Zee
HH
,
Boer
J
,
Prens
EP
.
Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity
.
J Am Acad Dermatol
.
2014
Sep
;
71
(
3
):
460
7
.
[PubMed]
0190-9622
19.
Shalom
G
,
Freud
T
,
Harman-Boehm
I
,
Polishchuk
I
,
Cohen
AD
.
Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients
.
Br J Dermatol
.
2015
Aug
;
173
(
2
):
464
70
.
[PubMed]
0007-0963
20.
Vazquez
BG
,
Alikhan
A
,
Weaver
AL
,
Wetter
DA
,
Davis
MD
.
Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota
.
J Invest Dermatol
.
2013
Jan
;
133
(
1
):
97
103
.
[PubMed]
0022-202X
21.
Wertenteil
S
,
Strunk
A
,
Garg
A
.
Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa
.
J Am Acad Dermatol
.
2019
May
;
80
(
5
):
1308
13
.
[PubMed]
0190-9622
22.
Garg
A
,
Strunk
A
,
Midura
M
,
Papagermanos
V
,
Pomerantz
H
.
Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis
.
Br J Dermatol
.
2018
Mar
;
178
(
3
):
697
703
.
[PubMed]
0007-0963
23.
Reddy
S
,
Orenstein
LA
,
Strunk
A
,
Garg
A
.
Incidence of long-term opioid use among opioid-naïve patients with hidradenitis suppurativa in the United States
.
JAMA Dermatol
.
2019
Sep
;
155
(
11
):
1284
90
.
[PubMed]
2168-6068
24.
Garg
A
,
Papagermanos
V
,
Midura
M
,
Strunk
A
.
Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A
.
Br J Dermatol
.
2018
Mar
;
178
(
3
):
709
14
.
[PubMed]
0007-0963
25.
Garg
A
,
Birabaharan
M
,
Strunk
A
.
Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States
.
J Am Acad Dermatol
.
2018
Jul
;
79
(
1
):
71
6
.
[PubMed]
0190-9622
26.
Garg
A
,
Papagermanos
V
,
Midura
M
,
Strunk
A
,
Merson
J
.
Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States
.
J Am Acad Dermatol
.
2018
Sep
;
79
(
3
):
495
500.e1
.
[PubMed]
0190-9622
27.
Arcavi
L
,
Benowitz
NL
.
Cigarette smoking and infection
.
Arch Intern Med
.
2004
Nov
;
164
(
20
):
2206
16
.
[PubMed]
0003-9926
28.
Shah
BR
,
Hux
JE
.
Quantifying the risk of infectious diseases for people with diabetes
.
Diabetes Care
.
2003
Feb
;
26
(
2
):
510
3
.
[PubMed]
0149-5992
29.
Muller
LM
,
Gorter
KJ
,
Hak
E
,
Goudzwaard
WL
,
Schellevis
FG
,
Hoepelman
AI
, et al
Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus
.
Clin Infect Dis
.
2005
Aug
;
41
(
3
):
281
8
.
[PubMed]
1058-4838
30.
Ray
GT
,
Suaya
JA
,
Baxter
R
.
Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study
.
BMC Infect Dis
.
2013
May
;
13
(
1
):
252
.
[PubMed]
1471-2334
31.
Murphy
EL
,
DeVita
D
,
Liu
H
,
Vittinghoff
E
,
Leung
P
,
Ciccarone
DH
, et al
Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study
.
Clin Infect Dis
.
2001
Jul
;
33
(
1
):
35
40
.
[PubMed]
1058-4838
32.
Miller
LG
,
Eisenberg
DF
,
Liu
H
,
Chang
CL
,
Wang
Y
,
Luthra
R
, et al
Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005-2010
.
BMC Infect Dis
.
2015
Aug
;
15
(
1
):
362
.
[PubMed]
1471-2334
33.
Janssen
KJ
,
Moons
KG
,
Kalkman
CJ
,
Grobbee
DE
,
Vergouwe
Y
.
Updating methods improved the performance of a clinical prediction model in new patients
.
J Clin Epidemiol
.
2008
Jan
;
61
(
1
):
76
86
.
[PubMed]
0895-4356
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.